Literature DB >> 32320003

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Safiya Richardson1,2, Jamie S Hirsch1,2,3, Mangala Narasimhan2, James M Crawford2, Thomas McGinn1,2, Karina W Davidson1,2, Douglas P Barnaby1,2, Lance B Becker2, John D Chelico1,2, Stuart L Cohen1,2, Jennifer Cookingham1, Kevin Coppa3, Michael A Diefenbach1, Andrew J Dominello1, Joan Duer-Hefele1, Louise Falzon1, Jordan Gitlin2, Negin Hajizadeh1,2, Tiffany G Harvin1, David A Hirschwerk2, Eun Ji Kim1,2, Zachary M Kozel2, Lyndonna M Marrast1,2, Jazmin N Mogavero1, Gabrielle A Osorio1, Michael Qiu3, Theodoros P Zanos4.   

Abstract

Importance: There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19). Objective: To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system. Design, Setting, and Participants: Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates. Exposures: Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission. Main Outcomes and Measures: Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected.
Results: A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/min, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. As of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1). Conclusions and Relevance: This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.

Entities:  

Mesh:

Year:  2020        PMID: 32320003      PMCID: PMC7177629          DOI: 10.1001/jama.2020.6775

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

2.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.

Authors:  Matt Arentz; Eric Yim; Lindy Klaff; Sharukh Lokhandwala; Francis X Riedo; Maria Chong; Melissa Lee
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

3.  Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.

Authors:  Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher
Journal:  Circulation       Date:  2005-05-16       Impact factor: 29.690

4.  Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.

Authors:  Catherine G Derington; Jordan B King; Jennifer S Herrick; Daichi Shimbo; Ian M Kronish; Joseph J Saseen; Paul Muntner; Andrew E Moran; Adam P Bress
Journal:  Hypertension       Date:  2020-03-09       Impact factor: 10.190

Review 5.  Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies.

Authors:  Zhengming Chen; Richard Peto; Maigeng Zhou; Andri Iona; Margaret Smith; Ling Yang; Yu Guo; Yiping Chen; Zheng Bian; Garry Lancaster; Paul Sherliker; Shutao Pang; Hao Wang; Hua Su; Ming Wu; Xianping Wu; Junshi Chen; Rory Collins; Liming Li
Journal:  Lancet       Date:  2015-10-10       Impact factor: 79.321

6.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

7.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

8.  Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?

Authors:  Rami Sommerstein; Michael M Kochen; Franz H Messerli; Christoph Gräni
Journal:  J Am Heart Assoc       Date:  2020-04-01       Impact factor: 5.501

  8 in total
  2000 in total

Review 1.  The complement system in COVID-19: friend and foe?

Authors:  Anuja Java; Anthony J Apicelli; M Kathryn Liszewski; Ariella Coler-Reilly; John P Atkinson; Alfred Hj Kim; Hrishikesh S Kulkarni
Journal:  JCI Insight       Date:  2020-08-06

2.  Neuroimaging Findings in Patients with COVID-19.

Authors:  P Nicholson; L Alshafai; T Krings
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-11       Impact factor: 3.825

3.  Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.

Authors:  Beatriz Mateos; Esteban Sáez-González; Inés Moret; David Hervás; Marisa Iborra; Elena Cerrillo; Luis Tortosa; Pilar Nos; Belén Beltrán
Journal:  Dig Dis       Date:  2020-04-23       Impact factor: 2.404

4.  The Natural History of a Patient With COVID-19 Pneumonia and Silent Hypoxemia.

Authors:  Nicholas Hornstein; Gilad M Jaffe; Kelley Chuang; Jaime Betancourt; Guy W Soo Hoo
Journal:  Fed Pract       Date:  2021-04

Review 5.  Impact of COVID-19 pandemic on chronic diseases care follow-up and current perspectives in low resource settings: a narrative review.

Authors:  Ginenus Fekadu; Firomsa Bekele; Tadesse Tolossa; Getahun Fetensa; Ebisa Turi; Motuma Getachew; Eba Abdisa; Lemessa Assefa; Melkamu Afeta; Waktole Demisew; Dinka Dugassa; Dereje Chala Diriba; Busha Gamachu Labata
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-06-15

6.  Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Authors:  Aaron C Petrey; Fares Qeadan; Elizabeth A Middleton; Irina V Pinchuk; Robert A Campbell; Ellen J Beswick
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 4.962

7.  A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.

Authors:  Jessica P Ridgway; Brianna Farley; Jean-Luc Benoit; Christopher Frohne; Aniruddha Hazra; Natasha Pettit; Mai Pho; Kenneth Pursell; Jina Saltzman; Jessica Schmitt; Arno Ziggy Uvin; David Pitrak; Moira McNulty
Journal:  AIDS Patient Care STDS       Date:  2020-05-29       Impact factor: 5.078

8.  Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series.

Authors:  Anish R Mitra; Nicholas A Fergusson; Elisa Lloyd-Smith; Andrew Wormsbecker; Denise Foster; Andrei Karpov; Sarah Crowe; Greg Haljan; Dean R Chittock; Hussein D Kanji; Mypinder S Sekhon; Donald E G Griesdale
Journal:  CMAJ       Date:  2020-05-27       Impact factor: 8.262

9.  BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.

Authors:  Magali Noval Rivas; Joseph E Ebinger; Min Wu; Nancy Sun; Jonathan Braun; Kimia Sobhani; Jennifer E Van Eyk; Susan Cheng; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 10.  Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.

Authors:  Krishna Sriram; Rohit Loomba; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.